Immunotherapy by recombinant antibodies

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Immunotherapy by recombinant antibodies

Translational research of the Immunity and cancer, participates in developing new immunotherapy treatments towards clinics. Innovative treatments are being validated in vitro on human cells and in vivo in relevant animal models. Investigational studies are also conducted on samples obtained from cancer patients treated by immunotherapy.The analysis of the immunological status of these patients before and after their treatment allows a better understanding of 1) the underlying mechanism of action of immunotherapies, 2) the prognostic value of immunological parameters and 3) the possible use of immune parameters to better design personalized treatments. About 20 individuals and 10 medical doctors of hospital are involved in such translational activities in immunotherapy.

Immunotherapy aims at using the immune system as a weapon to destroy tumor cells, especially the disseminated disease such as metastases that are often inaccessible to conventional treatments. Immunotherapy based on the use of recombinant antibodies against tumor antigens has the advantage of being targeted towards tumor cells and to spare normal ones hereby diminishing nonspecific toxicities.

The translational research in immunotherapy is structured in 3 programs that range from applied research to clinical studies including pre-clinical validation: Therapeutic antibodies, Anti-tumor vaccination and Tumor micro-environment.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger